Development of Monoclonal Antibodies against CMP-N-Acetylneuraminate-beta-galactosamide-alpha-2,3-si...
Development of Monoclonal Antibodies against CMP-N-Acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 1 (ST3Gal-I) Recombinant Protein Expressed in E. coli
About this item
Full title
Author / Creator
Publisher
Cairo, Egypt: Hindawi Limiteds
Journal title
Language
English
Formats
Publication information
Publisher
Cairo, Egypt: Hindawi Limiteds
Subjects
More information
Scope and Contents
Contents
Aberrant glycosylation is one of the major hallmarks of cancer with altered gene expression signatures of sialyltransferases. ST3Gal-I, a sialyltransferase, is known to play a crucial role in sialylation of T antigen in bladder cancer and it has reported elevated expression in breast carcinogenesis with increased tumor progression stages. The aim o...
Alternative Titles
Full title
Development of Monoclonal Antibodies against CMP-N-Acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 1 (ST3Gal-I) Recombinant Protein Expressed in E. coli
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_dd76b658faae4ae99a8f449560aef36f
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_dd76b658faae4ae99a8f449560aef36f
Other Identifiers
ISSN
2090-2247
E-ISSN
2090-2255
DOI
10.1155/2015/767204
